Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

NOT YET RECRUITING

NCT07214454

TCDS for the Treatment of Chronic Migraine

Sponsor: University College, London

View on ClinicalTrials.gov

Summary

Migraine affects 1 in 7 people worldwide, but for those suffering from chronic migraine there is a need for safe, effective and well tolerated treatments. The Nettle device is a non-invasive device, which is worn like a headband and delivers electrical stimulation (known as transcranial direct current stimulation or TCDS) to areas of the brain known to be involved in the processing of pain. In this study, 20 patients will be trained on how to use the device and then use it daily at home for 20 minutes for three months. Patients will complete a headache diary and quality of life questionnaires before using the device, during and after. As this is a feasibility study, adherence to completing the diaries and questionnaires will be assessed. Compliance with the treatment paradigm will also be assessed.

Official title: An Open Label, Single-site Feasibility Study of Transcranial Direct Current Stimulation (tCDS), Using the Nettle Device, for the Treatment of Chronic Migraine.

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2026-02-01

Completion Date

2026-06-01

Last Updated

2025-12-04

Healthy Volunteers

Conditions

Chronic Migraine Headache Transcranial Direct Current Stimulation

Interventions

DEVICE

Transcranial direct current stimulation (Nettle device) 2mA stimulation for 20 minutes per day

The Nettle device, manufactured by Samphire Neuroscience, contains four electrodes, two of which provide stimulation to the primary motor cortex (M1), and two stimulate the dorsolateral prefrontal cortex (DLPFC). A treatment session consists of 2mA stimulation for 20 minutes per day. Nettle is a Class IIa medical device which has a CE mark and is currently marketed for use in dysmenorrhoea and the mood component of premenstrual syndrome.

Inclusion Criteria: 1. Subjects aged 18-70 years 2. Fulfil the International Classification of Headache Disorders -3 (ICHD-3) criteria for chronic migraine, diagnosed by a headache specialist, at least 1 year prior to entering the trial 3. Subject is willing to keep headache medications stable for two weeks prior to entering the study and for the duration of the study. 4. Access to a smart phone to use the mobile application to control the device and use the Headache Pro app to record headaches. A paper diary may be used instead of the Headache Pro app Id required by individual patients. 5. Subject is able to provide written informed consent prior to participation in the study 6. Females of childbearing potential agree to use an effective method of contraception from the time consent is signed until treatment discontinuation. Effective methods of contraception acceptable for this trial are the oral contraceptive pill, patch, implant, injection, ring, intra-uterine system, copper coil, barrier methods, partner vasectomy or abstinence. Participants are considered not of child bearing potential if they are surgically sterile (i.e. they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal 7. If there is any possibility of pregnancy, females of childbearing potential should have a negative pregnancy test within 7 days of commencing the treatment phase. 8. Subject must be willing and able to provide written informed consent. Exclusion Criteria: 1. Epilepsy or history of seizures 2. Current or planned pregnancy during the study timeframe 3. Active suicidal thoughts 4. Pre-existing neurological or neuropsychiatric condition 5. Lesion, tumour or other defect in skull or brain 6. Implant inside skill, cochlear implant or implanted hearing aid. 7. Implanted medical device e.g. pacemaker or neurostimulator 8. Use of other stimulation devices such as spinal cord stimulators, vagal nerve stimulation, auricular nerve stimulator or deep brain stimulation. 9. Concurrent medication overuse 10. Use of cranial botulinum toxin injections or CGRP inhibitors in the past 6 months 11. Current or recent (within three months) participation in another clinical trial. 12. Planned surgical or significant medical intervention during the study period which may affect the study results, at the discretion of the chief investigator. 13. Lacking mental capacity to give informed written consent.